MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Risk of Motor Complications in Early Parkinson’s Disease Patients Treated with Opicapone in the EPSILON study: Effect of Levodopa Dose

    J. Ferreira, O. Rascol, F. Stocchi, A. Antonini, H. Brigas, J. Moreira, JF. Rocha, M. Fonseca, D. Ramos, J. Holenz, W. Poewe (Lisbon, Portugal)

    Objective: This post-hoc analysis of the EPSILON study evaluated whether levodopa dose (<400mg/day vs. ≥400mg/day) and opicapone (OPC) timing (at double-blind [DB] or open-label extension…
  • 2025 International Congress

    Heat Map Visualization of Improved Best ON Time in People With Parkinson’s Disease Treated With Foscarbidopa/Foslevodopa

    T. Henriksen, R. Hauser, I. Malaty, T. Kimber, M. Soileau, L. Bergmann, L. Harmer, J. Homola, R. Gupta, C. Yan, B. Bergmans (North Chicago, USA)

    Objective: Assess the impact of foscarbidopa/foslevodopa (CDp/LDp) continuous subcutaneous infusion (CSCI) on the motor states of people with Parkinson’s disease (PD) across 24 hours via…
  • 2025 International Congress

    Evaluation of Impact of Helicobacter Pylori Eradication on Symptomatology and Quality of Life in Parkinson’s Disease

    A. Kakkar, G. Vishwas, S. Mehta, S. Pattanaik, S. Bhattacharyya, V. Sharma, M. Modi (Chandigarh, India)

    Objective: This study aimed to determine the effects of Helicobacter Pylori(HP) eradication treatment on motor and non-motor symptoms and quality of life of PD patients…
  • 2025 International Congress

    Effect of Opicapone on Sleep-Related Complaints and Non-Motor Burden in Parkinson’s Patients: A Post-Hoc Analysis of the OASIS Trial

    J. Ferreira, M. Gago, R. Costa, M. Fonseca, H. Brigas, D. Martins, J. Holenz, C. Trenkwalder (Lisbon, Portugal)

    Objective: To assess the effect of opicapone (OPC) on different sleep complaints and non-motor symptoms (NMS) in fluctuating Parkinson’s disease (PD) patients with sleep disturbances.…
  • 2025 International Congress

    Immediate Impact of Whole-Body Vibration on Backward Walking in Individuals with Parkinson disease

    A. Boddy, K. Barta, M. Flores, K. Sawyer, L. Perry, A. Campbell (Waco, USA)

    Objective: Determine the immediate impact of performing partial squats using whole-body vibration (WBV) versus level surface on backward walking velocity in People with Parkinson Disease.…
  • 2025 International Congress

    Unilateral focused ultrasound subthalamotomy in early Parkinson’s disease: randomized-controlled trial protocol

    R. Martinez-Fernandez, MC. Rodriguez Oroz, S. Paschen, C. Juri, M. Del Alamo, E. Natera-Villalba, R. Rodriguez-Rojas, LH. Gonzalez-Quarante, M. Synowitz, J. Lorenzoni, CA. Sánchez-Catasús, S. Obika, T. Jimenez-Castellanos, P. Reiters, E. Cerutti, RA. Villino-Boquete, C. Ferrer, O. Rascol, G. Deuschl, JA. Obeso (Madrid, Spain)

    Objective: To describe the protocol of a multicenter, prospective, randomized controlled trial (EarlyFocus II) which evaluates the efficacy and safety of unilateral magnetic resonance-guided focused…
  • 2025 International Congress

    A randomised controlled feasibility study of a technology-assisted home-based aerobic exercise program for individuals with Parkinson’s disease

    S. Neo, Z. Yee, W. Li, HL. Ng, R. Hoe, C. Chung (Singapore, Singapore)

    Objective: The study evaluates the effectiveness of Combat PD, a mobile app designed to remotely deliver and monitor gamified aerobic exercise in promoting adherence and…
  • 2025 International Congress

    Effect of CUE1+ Device on Motor and Non-Motor Symptoms in Parkinson’s: A Pilot Randomised Controlled Trial.

    V. Azoidou, K. Rowsell, E. Camboe, K. Dey, A. Zirra, C. Quah, T. Boyle, C. Budu, D. Gallagher, A. Noyce, C. Simonet (London, United Kingdom)

    Objective: To assess the effect CUE1+ device on motor and non-motor symptoms in people with Parkinson’s (PwP). Background: Current treatments for PwP often fail to…
  • 2025 International Congress

    VGN-R09b, an Adeno-associated virus-based Combination Gene Replacement Therapy for Parkinson’s Disease

    YZ. Tao, SS. Tian, L. Lu, X. Zhu, H. Lv, XP. Zhao (Shanghai, China)

    Objective: Develop a sustained disease modifying gene therapy for treating Parkinson’s disease Background: Parkinson’s disease (PD) is characterized by the progressive loss of dopaminergic neurons…
  • 2025 International Congress

    Honey products in Parkinson’s disease – randomized placebo-controlled double-blind pilot study

    T. Endo, K. Toyooka, T. Matsumura, C. Mori, T. Saito, T. Saito, S. Sakoda (Toyonaka, Japan)

    Objective: The purpose of this study is to examine whether consumption of honey products can improve symptoms and their diurnal fluctuations in patients with Parkinson's…
  • « Previous Page
  • 1
  • …
  • 294
  • 295
  • 296
  • 297
  • 298
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley